Loading
A phase 3 trial in pancreatic cancer, run by Elisabethinen Hospital, now recruiting.
Liquid Biopsy (ctDNA) Guided Treatment in Localized Pancreatic Cancer: Neoadjuvant CTX vs. Upfront Surgery is a phase 3, interventional study registered as NCT06391892 by Elisabethinen Hospital, with a registry enrolment figure of 100 participants, started 2024-01-11 and due to reach its primary completion in 2025-12-31. Interventions recorded: Neoadjuvant chemotherapy instead of upfront surgery; Upfront surgery. Conditions listed: Pancreatic Cancer; Circulating Tumor Cell; Predictive Cancer Model. Primary outcome: DFS. Pancreatic eligibility wording from the registry: "* localized pancreatic cancer to go for upfront surgery". Sites: Austria. No results are recorded here; the registry entry is the source.
Shares Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.